We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 12.9% in Session
Read MoreHide Full Article
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) was a big mover last session, as the company saw its shares rise more than 12% on Friday. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $27.50 to $32.25 in the past one-month time frame.
The move came after the U.S. Food and Drug Administration has approved the company’s supplemental new drug application (sNDA) in order to widen the use of EXPAREL block to produce postsurgical regional analgesia.
The company has not seen any estimate revisions over the past one month, while the Zacks Consensus Estimate for the current quarter also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Pacira Pharmaceuticals currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.
Is PCRX going up? Or down? Predict to see what others think: Up or Down
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Image: Bigstock
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 12.9% in Session
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) was a big mover last session, as the company saw its shares rise more than 12% on Friday. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $27.50 to $32.25 in the past one-month time frame.
The move came after the U.S. Food and Drug Administration has approved the company’s supplemental new drug application (sNDA) in order to widen the use of EXPAREL block to produce postsurgical regional analgesia.
The company has not seen any estimate revisions over the past one month, while the Zacks Consensus Estimate for the current quarter also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Pacira Pharmaceuticals currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.
Pacira Pharmaceuticals, Inc. Price
Pacira Pharmaceuticals, Inc. Price | Pacira Pharmaceuticals, Inc. Quote
A better-ranked stock in the Medical - Drugs industry is BioSpecifics Technologies Corp. , which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is PCRX going up? Or down? Predict to see what others think: Up or Down
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>